Increased confidence in 2026 sales growth guidance of 8-10%
Edwards Lifesciences reported a strong Q4 with TAVR growing 10.6%, driven by clinical evidence and share gains from Boston Scientific's exit. Management raised confidence in 2026 guidance, citing durable growth catalysts from early TAVR data, European guideline changes, and upcoming NCD reconsideration. Key non-obvious insight: the current growth is fueled by symptomatic patient urgency, not asymptomatic expansion, with leading indicators suggesting sustained momentum. TAVR Q4 sales $1.16B +10.6% YoY, with share gains from Boston Scientific's exit in Europe proving sticky.
Buzzberg readIncreased confidence in 2026 sales growth guidance of 8-10%Edwards Lifesciences reported a strong Q4 with TAVR growing 10.6%, driven by clinical evidence and share gains from Boston Scientific's exit. Management raised confidence in 2026 guidance, citing durable growth catalysts from early TAVR data, European guideline changes, and upcoming NCD reconsideration. Key non-obvious insight: the current growth is fueled by symptomatic patient urgency, not asymptomatic expansion, with leading indicators suggesting sustained momentum. TAVR Q4 sales $1.16B +10.6% YoY, with share gains from Boston Scientific's exit in Europe proving sticky.Read full analysisCollapse analysis
Edwards Lifesciences reported a strong Q4 with TAVR growing 10.6%, driven by clinical evidence and share gains from Boston Scientific's exit. Management raised confidence in 2026 guidance, citing durable growth catalysts from early TAVR data, European guideline changes, and upcoming NCD reconsideration. Key non-obvious insight: the current growth is fueled by symptomatic patient urgency, not asymptomatic expansion, with leading indicators suggesting sustained momentum. TAVR Q4 sales $1.16B +10.6% YoY, with share gains from Boston Scientific's exit in Europe proving sticky.
TMTT sales grew >40% to $156M, crossing $500M full-year; Sapien M3 launch underway in US and Europe.
2026 guidance: 8-10% total sales growth, EPS $2.90-$3.05, with higher growth in H1 due to tough comps in H2.
Early TAVR data is shifting treatment urgency for symptomatic patients, not yet asymptomatic; claims show rising echoes, referrals, and stress tests as leading indicators.
Revenue$1.5696B
+1% QoQ
EPS$0.58
-13% QoQ
Gross margin78.3%
reported
Op margin23.59%
reported
What changed this quarter
01
Guidance
Increased confidence in 2026 sales growth guidance of 8-10%
Guidance · revenue to 9%
02
Demand
Early TAVR and long-term data driving growth
Management expressed increased confidence in 2026 guidance and highlighted multiple growth catalysts, citing strong results and strategic investments.
03
Demand
TAVR procedure growth high single digit, share gains sticky
Early TAVR and long-term data driving growth. Management expressed increased confidence in 2026 guidance and highlighted multiple growth catalysts, citing strong results and strategic investments.
04
Demand
TMTT growth over 40% driven by portfolio expansion
Early TAVR and long-term data driving growth. Management expressed increased confidence in 2026 guidance and highlighted multiple growth catalysts, citing strong results and strategic investments.
Demand & capex
Demand
Bookings & conversion
Early TAVR and long-term data driving growth. Management expressed increased confidence in 2026 guidance and highlighted multiple growth catalysts, citing strong results and strategic investments.
Capex
Investment and capacity
Management is increasing production capacity to keep up with growth in TAVR, TMTT, and surgical, with additional manufacturing expenses related to the fast expansion of new therapies impacting gross margin expectations.
Tone · Confident
Management expressed increased confidence in 2026 guidance and highlighted multiple growth catalysts, citing strong results and strategic investments.
Supply-chain alpha
A1
Early TAVR data is driving growth in symptomatic severe AS patients, not asymptomatic — claims data show no wave of asymptomatic treatment yet, but leading indicators (echoes, referrals, stress tests) are rising sharply.
“When we look at the claims data, we don't see asymptomatic patients coming in in waves through the claims data. What we do see… increase in the number of echoes… increase in the number of referrals… decrease in time from referral to CT… in…”
Early TAVR data is driving growth in symptomatic severe AS patients, not asymptomatic — claims data show no wave of asymptomatic treatment yet, but leading indicators (echoes, referrals, stress tests) are rising sharply.